Context: Evaluarea rolului prognostic al tomografiei cu emisie de pozitroni/computer tomograf (PET-CT) şi al ecoendoscopiei (EUS) efectuate înainte de chimioterapia neoadjuvantă (NAC) şi înainte de intervenţia chirurgicală pentru adenocarcinom esofagian (OAC), cu accent pe evaluarea ganglionilor limfatici (LN). Metode: Pacienţi suferind de OAC, trataţi într-un centru terţiar în perioada ianuarie 2008 -decembrie 2014 au fost incluşi într-un studiu retrospectiv. Toţi pacienţii au fost supuşi evaluării cu PET-CT şi EUS înainte de NAC şi esofagectomie. Au fost înregistrate informaţii privind evaluarea PET-CT cu FDG a ganglionilor locali, valoarea SUV a tumorii primare, ganglionii pozitivi şi mărimea tumorii în urma EUS. Au fost efectuate analize univariate şi multivariate, şi studii de supravieţuire. Rezultate: Studiul a inclus 151 de pacienţi care au îndeplinit criteriile de admitere (vârsta medie 62 de ani). Sensibilitatea PET-CT şi EUS pentru metastazele ganglionilor limfatici locali a fost de 39,2% şi 88,6%, cu o specificitate de 83,33% şi respectiv 19,15%. Nu au existat diferenţe de supravieţuire globală (OS) între pacienţii cu ganglioni limfatici identificaţi prin PET-CT cu FDG şi cei cu ganglioni limfatici negativi (p=0.347). Valoarea maximă de absorbţie standardizată (SUVmax) a fost divizată în ridicată şi
Introduction
The use of Positron Emission Tomography (PET), especially when combined with Computed Tomography (CT) has significantly improved the initial staging of oesophageal cancer patients, compared with traditional CT scan alone (1) . PET/CT has been shown to detect metastatic disease in an additional 10% of patients who were presumed only to have locoregional disease based on other staging modalities, and changes management overall in 15-20% of cases (2) . Lymph node involvement is an important prognostic indicator and multiple positive lymph nodes are considered a surrogate marker of systemic disease. As a result, most patients undergo neo-adjuvant treatment prior to surgical resection (3) . Historically, initial staging modalities, such as PET/CT and Endoscopic Ultrasound (EUS), have shown relatively poor accuracy in lymph node assessment in oesophageal adenocarcinoma patients (4, 5) .
The aim of this study was to determine the prognostic role of parameters measured by PET/CT and EUS before neoadjuvant chemotherapy and surgery, for oesophageal adenocarcinoma. Specifically, we sought to validate previous studies that demonstrated PET fluorodeoxyglucose (FDG)-avid lymph nodes to be prognostic, independent of final tumour stage.
Material and Method
This was a retrospective-cohort study taken from a prospectively maintained database of 705 patients, treated by oesophagectomy in a single tertiary center between January 2008 and December 2014. PET imaging was not performed routinely in our unit prior to 2007 and only patients with adenocarcinoma of the oesophagus or gastro-oesophageal junction (GOJ), Siewert Type 1 and 2 were included in the study cohort. Patients with squamous cell carcinoma or other rarer pathologies (sarcoma, GIST, benign lesions) and those without available PET imaging were excluded from the study cohort.
After initial diagnosis with oesophago-gastroduodenoscopy (OGD) and biopsy, patients were staged using multidetector CT (chest/abdomen/ pelvis), EUS, FDG-PET/CT and staging laparoscopy, the latter used selectively in patients with tumour extension below the diaphragm. All patients were managed through a dedicated multidisciplinary team meeting (MDT).
PET/CT and EUS were performed the same day as a part of a one-stop service provided for these patients, and endoscopy (two Consultant Gastroenterologists) and radiology (two Radiology-PET/CT Consultants) dedicated teams were blinded apart from the tumour location in their staging assessments.
For the study, specific FDG-PET/CT findings were recorded and analyzed: a. Maximum standardized uptake value (SUV max) of the primary lesion (divided into two groups by a median value of 10) b. FDG-avid local lymph nodes. Local lymph nodes were considered as left gastric, paraoesophageal, subcarinal and aortopulmonary nodes. EUS parameters were also recorded: a. Presence or absence of suspicious lymph nodes, b. Primary tumour length.
Suspicious findings of lymph nodes on PET/CT were enlargement with concurrent necrosis or signs of extracapsular invasion, in the context of elevated SUVmax.
Following multi-disciplinary team consensus, most patients (T2 or greater and/or having suspicious lymph nodes on imaging) were considered for neo-adjuvant chemotherapy (NAC) followed by tailored surgery. NAC regimens followed established protocols based on randomized controlled trial data (6, 7) . A combination of Epirubicin, Cisplatin/ Oxaliplatin, and 5-Fluro-uracil/capecitabine (CF, ECF, ECX or EOX) was used in almost all patients (6) .
The surgical approach was tailored to the individual patient's tumour characteristics and included Ivor-Lewis, Left thoraco-abdominal and transhiatal oesophagectomy at the individual surgeon's discretion.
All specimens were examined by one of a dedicated team of upper gastro-intestinal histopathologists at a single centre. The AJCC/TNM 7th Edition was used for all cases. Where histopathology showed malignant cells within 1mm of the circumferential resection margin it was considered positive (R1) as per the Royal College of Pathologists criteria (8) .
Survival data were obtained from the unit database, hospital electronic administrative systems, or general practitioner records according to the last confirmed visit to any of the above. The date of surgery was used as the baseline for calculation of survival, and as time of death is defined as time of death from the disease. Recurrent disease was defined as the presence of radiological or histopathological evidence of recurrence as agreed by the MDT.
PET/CT suspicious for malignant involvement LNs were compared with final histopathological LN status using descriptive statistics. Univariate and multivariate Cox proportional hazards regression models were then conducted to identify which clinico-demographic characteristics were predictive for disease recurrence or overall death. The model was adjusted for age, tumour stage (I,II,III), Mandard Score (1-2-3,4-5), grade (well, moderately, poorly differentiated), lymphovascular invasion (positive, negative), resection status (R0, R1), PET LNs (positive, negative), SUVmax of the primary (>10, <10), EUS LNs (positive, negative).
Kaplan-Meier survival curves were plotted according to the presence or absence of FDGavid local lymph nodes. Comparisons between groups were made using the log rank test. Two-sided P values were calculated and p < 0.05 was considered significant.
Results
A total of 151 patients were included in the study cohort, (126 male;25 female), with a median age of 62. Demographics and relevant clinical parameters are presented in Table 1 .
FDG-avid local lymph nodes were reported accurately as positive in 38/151 (25.17%) patients ( Table 3 . In the multivariate model, no statistically significant difference between the two groups was found for PET avid LN's (HR (95% CI): OS 0.80(0.40-1.60), DFS 0.83 (0.38-1.79)) ( Table 4 ). Likewise, EUS LNs positive (HR (95% CI) OS: 2.79 (0.78-9.96), DFS:2.60 (0.63-10.70)),SUVmax of the primary tumour (>10) (HR (95% CI) OS: 0.64 (0.33-1.23), DFS:1.81 (0.80-4.08)) and EUS tumour length(HR (95% CI) OS:1.02 (0.90-1.16), DFS:1.02 (0.86-1.21)) did not independently predict survival ( 
Discussion
This study has demonstrated that initial staging investigations for oesophageal adenocarcinoma have limitations and should be interpreted cautiously before finalising patient specific treatment plans. The accuracy of local lymph node assessment remains low but PET/CT and EUS may have complimentary roles in its prediction. Positive lymph nodes on PET/CT and EUS were not independently prognostic, in contrast to the findings of other studies (9) (10) (11) . Some methodological issues deserve attention. This was a large study in terms of patient numbers, compared to the existing literature, with patients drawn from a single centre's prospectively maintained database with mature follow-up. The study population was homogenous, focusing on adenocarcinoma patients being treated with curative intent. Nonetheless, it was not a prospective study, and despite adjustments for known confounders, may have been susceptible to bias.
Staging accuracy is known to be user dependent and although the current study's staging results are in line with, or better than, the existing literature, variations in individual interpretation and advances in imaging technology ensure this is a continually evolving field. Several factors may contribute to the reduced sensitivity of PET/CT lymph node assessment. The 'partial volume effect', whereby local lymph nodes may be obscured by a metabolically active primary tumour, is known to influence the accuracy of PET/CT (12) . As mentioned above in this study, accumulating experience of dedicated teams increases sensitivity. There are no published guidelines or radiological consensus on the metabolic criteria required to report a positive lymph node (4) . It is also accepted that on histopathological examination a proportion of positive lymph nodes have micrometastases, without being enlarged (13) . As shown finally, there may be a down-staging effect of neoadjuvant chemotherapy, and the studied investigations were performed prior to neoadjuvant treatment. As a result of these factors, there is increasing interest in the literature in post-neoadjuvant treatment PET/CT for prognosis and treatment response assessment (14) (15) (16) . In principle, this would agree with work previously published by our group that tumour stage after neo-adjuvant chemotherapy is more important prognostically than staging performed at diagnosis (17) .
Previous studies have attempted to assess the value of PET/CT in predicting survival in oesophageal adenocarcinoma patients (9) . One important study reported on a cohort of 121 patients, concluding that FDG-avid local lymph nodes adversely influenced disease-free and overall survival, while SUVmax and tumour length did not (9) . Interestingly this prognostic role for PET/CT avid lymph nodes was also present in the context of poor overall sensitivity for pathologically confirmed lymph nodes, suggesting that high metabolic activity in local lymph nodes may be a surrogate for more advanced disease or adverse tumour biology.
This study's data also suggest that high SUVmax on PET/CT and increased tumour length on EUS do not correlate with recurrence or survival. The latter is consistent with several studies (9, 18) , and contradicts others (19, 20) . It has to be emphasized that these studies were small and included both adenocarcinoma and squamous cell carcinoma patients, without distinguishing between those patients having neoadjuvant treatment and primary surgery.
Most patients with oesophageal cancer being considered for resection present with locally advanced disease and, as a result, are considered for peri-operative chemotherapy. Specific lymph node status, whilst important for prognosis, seldom changes the management of these patients. However, certain scenarios do require accurate lymph node prediction. The management of early tumours with endoscopic mucosal resection mandates an accurate assessment of local lymph nodes to avoid under-treating disease, particularly as the indications for endoscopic therapy expand to include tumours with early submucosal extension (T1b) (21) . Likewise, primary surgery would not be normally considered in patients staged as lymph node positive. Additionally, with the recognition that multi-node positive patients have a high likelihood of systemic disease, the role of surgery is increasingly being questioned for this poor prognosis group. In all of the above scenarios, lymph node status could significantly alter patient management and the conspicuous differences in the sensitivity of PET/CT and EUS inevitably lead to the debate of how we balance the risks of over and undertreatment of oesophageal cancer (22, 23) .
Increasing experience with EUS and PET/CT have improved the accuracy of both modalities. The addition of fine needle aspiration (FNA) has also been shown to improve the sampling accuracy of EUS although conceivably at the risk of seeding the primary tumour (21) . Adding new parameters such as EUS elastography or PET/MRI (24, 25) , could potentially improve staging further. New molecular or metabolic techniques validated by high quality studies are undoubtedly needed to better assess tumour biology and response to chemotherapy.
Conclusions
In conclusion, this study has confirmed a low sensitivity for PET/CT and low specificity for EUS in the assessment of local LNs in oesophageal adenocarcinoma. These differences suggest the two modalities may be complimentary in local lymph node staging which remains one of the most important prognostic indicators in oesophageal cancer. PET/CT FDG-avid LNs, EUS lymph nodes, SUVmax of the primary tumour and EUS length did not independently predict prognosis in contrast to other studies in the literature. Post neo-adjuvant treatment imaging and staging modalities are important and need improvement in accuracy if we aspire to predict prognosis prior to surgery.
